FOR IMMEDIATE RELEASE
Research presentations span aortic stenosis discrimination, global longitudinal strain correlation, and cardiac timing interval validation — advancing the evidence base for SCG-based cardiac analysis.
SURREY, British Columbia — April 21, 2026 — LLA Technologies Inc. will present three research studies at the 2026 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions and CAIC-ACCI Summit, taking place April 23–25 at the Palais des Congrès de Montréal. The joint international conference brings together more than 1,900 interventional cardiologists, researchers, and clinical innovators from around the world.
The three presentations featuring the Recordis™ seismocardiography (SCG) system are:
- SCG-Derived Cardiac Timing Intervals (oral presentation). Correlation data between Recordis-derived and echocardiography-derived cardiac timing measurements, including ejection time and diastolic intervals. Presented by Dr. Jyotpal Singh.
- Identifying Aortic Stenosis Using Seismocardiography (poster). A study of symptomatic aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) and matched controls, evaluating an SCG-derived amplitude marker for discrimination between AS and non-AS patients, with an area under the ROC curve of 0.93 (95% CI 0.92–0.97).
- Correlation of Global Longitudinal Strain from Echocardiography to Seismocardiography (poster). Preliminary research examining the relationship between SCG-derived amplitude markers and echocardiography-derived GLS — a clinically important measure increasingly used in cardio-oncology and heart failure management.
The research builds on LLA’s previously published work demonstrating that cardiac timing changes following TAVI can be monitored using Recordis without additional staff, time, or equipment, with findings consistent with established echocardiographic measures (JACC: Advances, 2025).
“SCAI is one of the most rigorous scientific forums in interventional cardiology, and our presence here reflects where we are as a company — building the evidence base for seismocardiography as a research tool with growing clinical relevance,” said Dr. Payam Dehghani, Chief Medical Advisor at LLA Technologies. “Our goal at this conference is to engage with the academic community, share our data, and identify research partners whose work could benefit from standardized, reproducible cardiac timing analysis.”
“This body of work reflects several years of collaboration across multiple clinical sites and patient populations,” said Dr. Jyotpal Singh, lead investigator on the SCAI presentations. “We are grateful to the participating clinical teams and patients who have made this research possible. SCAI gives us the opportunity to share what we have learned with the broader interventional cardiology community — and to explore questions that will shape the next phase of validation.”
Seismocardiography is a non-invasive method that captures the mechanical activity of the heart through signals recorded on the chest wall. Recordis is a Health Canada Class II medical device with FDA 510(k) clearance pending. The system is designed to support research and clinical investigation in cardiac timing and valve function, and does not replace echocardiography or other established imaging modalities.
LLA Technologies is actively expanding its research collaboration network. Current multi-site partnerships extend across clinical research sites in New York, San Francisco, Calgary, and Quebec. A 500-patient multi-site validation study is currently underway, extending findings across broad clinical populations and grades of AS severity.
“After nearly two decades of R&D, the scientific foundation we have built is now being tested and validated in the most demanding clinical environments,” said Dave Loban, CEO of LLA Technologies. “SCAI represents an important step for the company. We are focused on partnering with the research community to advance what seismocardiography can contribute to cardiovascular care — and we are approaching this with the rigor and patience that serious clinical evidence requires.”
LLA Technologies will exhibit at SCAI 2026 for the duration of the conference. Researchers, clinical investigators, and institutional partners interested in discussing potential collaborations are invited to visit the booth or contact the team directly.
About LLA Technologies
Founded in 2007, LLA Technologies Inc. is an ISO 13485 and MDSAP certified Canadian medical device company. The company’s Recordis system is a Health Canada Class II approved medical device that captures cardiac mechanical signals through a non-invasive seismocardiography sensor and produces over 120 standardized cardiac timing metrics in under 60 seconds. Recordis is designed for scalable multi-site research deployment, with current validation studies underway in New York, San Francisco, and Calgary, and findings published in JACC: Advances and additional studies presented at SCAI 2026. The company is pursuing FDA 510(k) clearance. Learn more at recordis.ca
###
LLA Technologies Inc.
For more information:
[email protected]
LinkedIn